Our Commitment

Accessibility is integral to our mission of advancing science for all people. We strive to build and maintain digital experiences that empower every visitor to engage with our work, regardless of ability.

• We strive to conform to the Web Content Accessibility Guidelines (WCAG) 2.1, Level AA, as published by the World Wide Web Consortium (W3C).
• Our accessibility efforts are ongoing. We continuously evaluate and improve the user experience across all of our digital platforms, including our corporate website, clinical trial portals, and investor resources.
• Accessibility is not a one-time project — it is a core value embedded in our design, development, and content creation processes.

Conformance Status

We regularly assess our conformance to ensure we are meeting our accessibility goals. Below is a summary of our current status.

Technical Specifications

Our website relies on the following technologies to ensure accessibility conformance:

• HTML5 — Semantic markup for screen reader compatibility
• CSS3 — Responsive layouts and high-contrast styling
• JavaScript — Enhanced interactivity with progressive enhancement
• WAI-ARIA — Accessible Rich Internet Applications for complex UI patterns

Testing & Validation Tools

We test our digital content with the following assistive technologies and tools:

• NVDA (Windows screen reader)
• JAWS (Windows screen reader)
• VoiceOver (macOS and iOS)
• TalkBack (Android)
• WAVE Web Accessibility Evaluation Tool
• axe DevTools by Deque Systems

Compatible Browsers

Our website is tested and optimized for the latest two major versions of the following browsers:

• Google Chrome
• Mozilla Firefox
• Apple Safari
• Microsoft Edge

Known Limitations

While we strive for full accessibility, some areas of our website may have known limitations. We are committed to addressing these as quickly as possible.

• PDF Documents: Some older PDF documents, particularly legacy clinical and regulatory filings, may not be fully accessible. We are actively remediating these files with tagged, screen-reader-friendly versions.
• Third-Party Content: Some third-party embedded content (e.g., video players, interactive maps, or analytics tools) may not fully conform to WCAG 2.1 Level AA. We work with vendors to encourage accessibility improvements.
• Legacy Pages: Older sections of our website are being updated on a rolling basis to meet current accessibility standards.
• Response Time: We aim to address reported accessibility issues within 30 business days of notification.

Accessibility Features

We have implemented the following features to ensure an inclusive experience for all visitors:

Keyboard Navigation

All interactive elements — including menus, links, buttons, and form controls — are fully navigable using a keyboard alone. Tab order follows a logical reading sequence.

Screen Reader Support

We use semantic HTML elements and ARIA labels throughout our website to ensure content is accurately conveyed by screen readers.

Text Resizing

All content reflows correctly when text is resized up to 200% zoom without requiring horizontal scrolling. Our layouts are designed to be fluid and responsive.

Color Contrast

All text on our website meets or exceeds the WCAG 4.5:1 contrast ratio requirement for normal text and 3:1 for large text, ensuring readability for users with low vision or color deficiencies.

Alternative Text

All meaningful images include descriptive alternative text. Decorative images are marked appropriately so they are skipped by assistive technologies.

Captions & Transcripts

Video content includes closed captions and transcripts where available. We are working to caption all new and existing video assets in our media library.

Focus Indicators

Visible focus rings are applied to all interactive elements so keyboard users can always identify their current position on the page.

No Flashing Content

No content on our website flashes more than three times per second, in accordance with WCAG guidelines for seizure prevention.

Assistive Technology Compatibility

Our website is optimized for use with a wide range of assistive technologies:

• Screen Readers: Optimized for common screen readers including NVDA, JAWS, VoiceOver, and TalkBack.
• Screen Magnification: Compatible with built-in operating system magnification tools and third-party magnifiers such as ZoomText.
• Voice Recognition: Compatible with Dragon NaturallySpeaking and similar voice input software, allowing full navigation and interaction via voice commands.
• High-Contrast Mode: Our website respects operating system high-contrast settings, ensuring content remains legible and usable in all display modes.

Feedback & Contact

We welcome and value your feedback on the accessibility of our website. If you encounter any barriers or have suggestions for improvement, please let us know.

• Email: privacy@jurutherapeutix.com
• Suggested Subject Line: “Accessibility Feedback – [Page Name]”

When contacting us, please include:

• The URL or page name where you experienced the issue
• A description of the problem encountered
• The assistive technology you were using (if applicable)
• Your preferred method of contact

Alternative Formats: Content is available in alternative formats upon request, including large print, audio descriptions, and braille coordination through our accessibility team.

Formal Complaints

If you are not satisfied with our response to your accessibility feedback, you have the right to escalate your concern through the appropriate regulatory channels.

• United States: Contact the ADA National Network at adata.org or call 1-800-949-4232 for information about your rights under the Americans with Disabilities Act.
• European Union / United Kingdom: Contact your national accessibility enforcement body. In the UK, this is the Equality and Human Rights Commission (EHRC). In EU member states, please refer to the European Accessibility Act enforcement authorities.

We take all complaints seriously and will work with the relevant authorities to resolve any issues promptly.

Our Accessibility Roadmap

Accessibility is an ongoing journey. Below is our planned roadmap for improving digital accessibility across Jsuru Therapeutix properties.

• Q3 2026: Full PDF remediation of clinical documents, including investigator brochures, study protocols, and patient-facing materials.
• Q4 2026: Enhanced video captioning library — all new and archival video content will receive professional-grade closed captions and transcripts.
• Q1 2027: Full WCAG 2.2 conformance audit conducted by an independent third-party accessibility consultancy.
• Q2 2027: Accessibility user testing sessions with disability communities to gather direct feedback and inform future improvements.

Additional Resources

For more information about web accessibility standards and your rights, please visit the following resources:

• Web Content Accessibility Guidelines (WCAG) 2.1 — The international standard for web accessibility published by the W3C Web Accessibility Initiative.
• ADA.gov — Official information and resources about the Americans with Disabilities Act from the U.S. Department of Justice.
• Section508.gov — Resources on Section 508 of the Rehabilitation Act, which establishes accessibility requirements for federal electronic and information technology.